Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative Hepatectomy with Lenvatinib and Durvalumab for Advanced HCC
NCT06470256Phase 1Recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and lenvatinib in hepatocellular carcinoma (HCC). Primary endpoint: Objective Response Rate. Started Jun 2024; status: recruiting.
02
Drugs
durvalumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06470256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470256.